Annotation Detail

Information
Associated Genes
RET
Associated Variants
RET OVEREXPRESSION ( ENST00000355710.8 )
RET OVEREXPRESSION ( ENST00000355710.8 )
Associated Disease
papillary adenocarcinoma
Source Database
CIViC Evidence
Description
A 78-year-old man presented with oral papillary adenocarcinoma and lung metastases that were refractory to standard treatment. Tumor sequencing showed increased MAPK activity due to RET over-expression and PTEN deletion, therefore sunitinib (RET inhibitor) was initiated. After 28 days post-administration, the lung metastases decreased in size by 22% (28mm to 21mm) and no new metastatic lesions had appeared. After 4 months, the patient grew resistant to treatment.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1518
Gene URL
https://civic.genome.wustl.edu/links/genes/42
Variant URL
https://civic.genome.wustl.edu/links/variants/597
Rating
3
Evidence Type
Predictive
Disease
Papillary Adenocarcinoma
Evidence Direction
Supports
Drug
Sunitinib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
20696054
Drugs
Drug NameSensitivitySupported
SunitinibSensitivitytrue